Opinion

Video

Future Directions in the Management of Multiple Myeloma

Author(s):

Alfred L. Garfall, MD

Alfred L. Garfall, MD, discusses his hopes for the future treatment landscape of multiple myeloma.

Video content above is prompted by the following questions:

  1. Please discuss any other data in multiple myeloma released at ASCO 2024 that you find noteworthy to share with colleagues.
  2. Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma? What can we look forward to through the end of the year and beyond?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Matias Sanchez, MD
Related Content
While immunogenicity is often reduced, vaccination remains indispensable in multiple myeloma, according to the review. | Image credit: alernon77 - stock.adobe.com
September 9th 2025

Vaccination Remains Essential in Multiple Myeloma Despite Impaired Responses

Kimberly Rath, PharmD
SWIFT-seq was able to successfully capture CTCs in 90% of patients with MGUS, SMM, and MM. | Image credit: luchschenF - stock.adobe.com
September 9th 2025

Novel Blood Test Could Transform Multiple Myeloma Diagnosis, Monitoring

Jared Kaltwasser
Whether KRd‐based quadruplets will redefine the frontline standard now hinges on proving they can deliver deeper, longer‐lasting remissions without compromising safety. | Image credit: Dzmitry - stock.adobe.com
September 9th 2025

Carfilzomib‐Based Quadruplets Challenge VRd as Frontline Multiple Myeloma Backbone

Kimberly Rath, PharmD
Myeloma cells | Image: ASH image bank
September 9th 2025

On the Path to Greater Precision in Treating Multiple Myeloma

Mary Caffrey
The model has the potential to boost early detection of MM and contribute to a paradigm shift in the treatment of MM. | Image credit: shidlovski - stock.adobe.com
September 9th 2025

Model Based on EHR Parameters Can Predict 5-Year Multiple Myeloma Risk

Jared Kaltwasser
Joseph Mikhael, MD | Image: T-GEN
September 9th 2025

How M-Power Is Building Trust to Raise Awareness of Multiple Myeloma in the Black Community

Joseph Mikhael, MD Interview by Mary Caffrey

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo